As the Q1 earnings period wraps up, it’s essential to evaluate the top and bottom performers in the medical devices and supplies sector, including Bausch + Lomb (NYSE:BLCO) and its competitors.
The medical devices sector combines consistent demand with substantial investments in innovation and adherence to regulations. Companies benefit from reliable revenue sources from consumables, maintenance services, and gradual technology upgrades, although specialized devices serve narrower markets. The capital-heavy nature of development, long regulatory timelines, and the requirement for clinical validations can negatively impact profitability. Furthermore, continuous pricing pressure from healthcare providers and insurers looking for cost efficiency poses additional challenges. However, an aging population increases chronic disease prevalence, boosting demand for medical interventions. Innovations in digital health, such as remote monitoring and smart devices, are anticipated to create further demand by expediting upgrade cycles. Conversely, the shift toward value-based care models presents obstacles due to pricing and reimbursement challenges, while integrating cybersecurity for connected devices complicates matters for manufacturers.
The seven specialty medical device stocks we monitor showed a solid performance in Q1, collectively surpassing analysts’ revenue expectations by 5.2%.
Following this update, share prices have remained stable, with an average negligible change since earnings releases.
Bausch + Lomb (NYSE:BLCO)
With nearly 170 years devoted to vision care, Bausch + Lomb (NYSE:BLCO) offers a extensive variety of eye health products, including contact lenses, medications, surgical devices, and consumer eye solutions.
Bausch + Lomb achieved revenues of $1.24 billion, representing a 9.4% year-over-year increase, which exceeded analysts’ expectations by 2.2%. The quarter proved excellent for the company, beating both EPS and revenue estimates.
Interestingly, shares rose 3% after the announcement, currently trading at $16.20.
Best Q1: STAAR Surgical (NASDAQ:STAA)
STAAR Surgical (NASDAQ:STAA) has successfully implemented over 2.5 million implants globally, creating lenses that rectify vision issues without removal of the eye’s natural lens.
The company reported revenues of $93.52 million, marking an astounding 120% increase year-over-year, significantly exceeding analysts’ expectations by 20.8%. The company performed remarkably well, surpassing both EPS and revenue estimates.
STAAR Surgical not only achieved the highest beat against analyst estimates but also the fastest revenue growth among its peers. The stock increased by 10.8% following this news, now trading at $32.58.
Weakest Q1: Inspire Medical Systems (NYSE:INSP)
Inspire Medical Systems (NYSE:INSP) offers an alternative to those who struggle with CPAP machines by developing an implantable neurostimulation device that treats obstructive sleep apnea by stimulating nerves to keep airways open during sleep.
The company reported revenues of $204.6 million, a modest 1.6% increase year-over-year, just surpassing analysts’ expectations by 1.9%. Nonetheless, it was deemed a slower quarter, as their full-year revenue guidance fell short of expectations.
Although Inspire Medical Systems raised full-year guidance, it presented the weakest performance against analyst expectations in the group. The stock experienced a significant decline of 22.9% since the report, currently priced at $42.30.
Integer Holdings (NYSE:ITGR)
Integer Holdings (NYSE:ITGR) provides outsourced medical device manufacturing, producing components for cardiac, vascular, neurological, and various medical uses.
The company reported revenues of $439.6 million, showing no change year-over-year, and exceeding analysts’ expectations by 2.8%. However, it experienced a notable miss against full-year EPS guidance.
Integer Holdings recorded the slowest revenue growth in its category. Since the report, shares have risen by 8.1%, currently trading at $90.46.
Enovis (NYSE:ENOV)
Specializing in restoring or maintaining natural motion for patients, Enovis (NYSE:ENOV) designs and manufactures orthopedic medical devices covering injury prevention, pain management, joint replacements, and rehabilitation.
Enovis reported revenues of $589.2 million, a 5.4% year-over-year increase, exceeding analysts’ expectations by 3.1%. Overall, it was a satisfactory quarter, though it exhibited the weakest full-year guidance update among peers.
Following this report, the stock rose by 3.7%, currently trading at $25.76.
Market Update
Concerns regarding artificial intelligence emerged in late 2025 into early 2026, affecting software companies who worried about declining pricing power. Similarly, crypto investors speculated about the long-term value of crypto infrastructures in the context of autonomous AI trading systems.
This led to a shift away from these sectors into safer investments. However, as spring 2026 arrived, the narrative shifted from technological disruptions to geopolitical risks, notably the U.S. conflict with Iran, altering market psychology and prompting investors to instead focus on oil supply, inflation, and global stability.
Interested in investing in strong companies with solid fundamentals? Explore our Top 6 Stocks and consider adding them to your watchlist, as they are well-positioned for growth regardless of the political or macroeconomic environment.
StockStory’s analyst team, composed of experienced investors, employs quantitative analysis and automation to deliver timely, market-leading insights.
